OnKure CFO receives 110,000 stock options

OnKure Therapeutics, Inc. reported that Chief Financial Officer Jason A. Leverone received an employee stock option grant covering 110,000 shares of Class A common stock.

Accepted by SEC EDGAR 04/03/2026 - 03:27 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. reported that Chief Financial Officer Jason A. Leverone received an employee stock option grant covering 110,000 shares of Class A common stock. The options have an exercise price of $4.07 per share and expire on March 31, 2036.

According to the vesting schedule, 1/48th of the shares subject to the option will vest on May 1, 2026 and monthly thereafter, as long as he continues as a service provider through each vesting date. Following this grant, he holds 110,000 stock options directly.

Insider Trade Summary

Grant/Award: 110,000 shares

Grant/Award 1 txn

Insider Leverone Jason A.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	110,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 110,000 contracts (Direct)

Footnotes (1)

1. F1. 1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Key Figures

Options granted: 110,000 options Exercise price: $4.07 per share Underlying shares: 110,000 shares +3 more

6 metrics

Options granted 110,000 options Employee stock option grant to CFO on April 1, 2026

Exercise price $4.07 per share Exercise price for the employee stock option grant

Underlying shares 110,000 shares Class A common stock underlying the options

Expiration date March 31, 2036 Option expiration for the CFO grant

Post-grant options held 110,000 options Total derivative securities following the transaction

Initial vesting date May 1, 2026 1/48th of option shares vest on this date

Key Terms

Employee Stock Option (right to buy), exercise price, expiration date, vesting

4 terms

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 4.0700 per share exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: options expire on 2036-03-31"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"1/48th of the shares subject to the option shall vest on May 1, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OnKure Therapeutics (OKUR) report for its CFO?

OnKure Therapeutics reported its CFO received an option grant for 110,000 shares of Class A common stock. This employee stock option has an exercise price of $4.07 per share and represents equity-based compensation rather than an open-market stock purchase or sale.

What is the exercise price of the OnKure (OKUR) CFO’s new stock options?

The CFO’s new employee stock options have an exercise price of $4.07 per share. This means he can buy OnKure Class A common stock at $4.07 if the options vest and are exercised before their March 31, 2036 expiration date.

How many stock options does the OnKure (OKUR) CFO hold after this Form 4?

After this grant, the CFO holds 110,000 employee stock options directly. These options are tied to 110,000 shares of Class A common stock and vest gradually over time according to the monthly vesting schedule described in the filing footnote.

What is the vesting schedule for the OnKure (OKUR) CFO’s option grant?

The option vests over four years, with 1/48th of the shares vesting on May 1, 2026 and monthly thereafter. Vesting continues only if the CFO remains a service provider to the company through each vesting date, aligning compensation with ongoing service.

When do the newly granted OnKure (OKUR) stock options expire?

The newly granted employee stock options expire on March 31, 2036. The CFO can exercise vested portions any time before this expiration date, subject to the option terms and continued service conditions described in the Form 4 and related footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leverone Jason A.

(Last) (First) (Middle)

C/O ONKURE THEREAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$4.07	04/01/2026		A		110,000		(1)	03/31/2036	Class A Common Stock	110,000	$0	110,000	D

Explanation of Responses:

1. 1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

	/s/ Rogan Nunn, by power of attorney	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)